1309 GMT - AstraZeneca's revenue miss in oncology segment should concern investors but its long-term story seems intact, Barclays analysts say in a note. The British pharma giant posted mixed 1Q results as some of its oncology and rare disease drugs fell short of company-compiled sales consensus, the analysts say. "While we believe investors would question the oncology misses, important catalyst readouts planned for later this year and AstraZeneca being less susceptible to the ever-emerging tariff situation in the U.S., we see AstraZeneca as best positioned in our coverage," they say. Shares are down 0.3% at 104.90 pounds. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
April 29, 2025 09:09 ET (13:09 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。